Inactivation of protein kinase Cδ on proliferation, apoptosis and related signaling pathways of human os-teosarcoma stem cellsLV Huicheng, JIA Haisheng, MA Min, WANG Mingbo, WU Yimin1057-1062
Reversal effect of miR-155 on the resistance of leukemia cells to adriamycin by regulating Ets-1 expressionSHA Min, YE Jun, GUO Ting, ZHANG Lixin, LUAN Zhengyun1063-1067
Function study of miR-26b targeting GSK-3βon the anti-stemness of breast cancer cellsMA Deliang, QIN Jing, ZHANG Dianfu1068-1073
Anti-proliferation effect of polyenephosphatidylcholine combined with oxaliplatin on gastric cancer cellsGAO Lei, ZHANG Hongjun, JIANG Tao, SONG Hao, ZHAO Yuanyuan, LIU Xiguang1074-1079
RAS, CD68 and CD34 expression in breast cancer tissue and their clinical significanceSHI Yue, YUAN Gaofeng, SHI Fengling, FENG Chengting, WU Baoan, LI Wei, TAO Min, LIANG Rongrui1080-1083
Expression of SATB1 in Xinjiang Uygur patients with breast cancer and its relationship with clinicopatho-logical featuresJIANG Weihua, SUN Xiaohong, LI Yongtao, ZHANG Mingshuai, WANG Xiaowen, OU Jianghua1084-1087
Relationship between the levels of VEGF, MMP-9 and chemotherapy effect in patients with advanced breast cancerLI Li, LIU Delin, WU Yuan, WANG Youqun, SUN Weili1088-1092
Expression and clinical significance of nr5A2 and GPC3 in human gastric cancer tissuesBI Ran, GAO Liming, LIU Lijie, ZHANG Shuang, JIN Tian, JIA Hongju, ZHENG Lei, HE Yuqing, FU Zhanzhao1093-1098
Expression and clinical significance of BLZF1 in human gastric cancer tissuesFENG Changyi, WU Haiyan, XU Zizhi, LIU Kaiyuan1099-1102
A single center, single arm and phase Ⅱ clinical trail：efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced NSCLC patients with secondary drug resistanceZHU Yanzhe, PAN Yueyin, DU Yingying, LIU Hu, MA Tai, SHEN Yuanyuan1103-1109
